Takeda计划开发norovirus疫苗

Takeda公司宣布公司计划开发针对norovirus病毒的疫苗。据估计美国每年有2100万人被该病毒所感染，大概800人每年死于这种病毒引发的疾病。此次Takeda公司研制的norovirus疫苗融合了两种亚型的norovirus病毒，因而能够有效保护接种者不受环境中不同病毒亚型的影响。其市场估计每年可达四亿美元。（生物谷Bioon.com）

详细英文报道：

Bloomberg has an extensive article today on Takeda's leading effort to develop a norovirus--or vomiting bug--vaccine that could prove a boon to the cruise ships and schools which are often afflicted with outbreaks. Every year about 21 million people in the U.S. are infected, and about 800 die. This experimental vaccine combines components of two types of norovirus, which Takeda believes should provide an effective guard against all the viral strains in circulation. And some analysts believe it could be worth up to $400 million a year in revenue if Takeda can get an approval ahead of its rivals.http://www.xiyam.com/